These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 17539776)

  • 1. High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma.
    Tecchio C; Nadali G; Scapini P; Bonetto C; Visco C; Tamassia N; Vassilakopoulos TP; Pangalis GA; Calzetti F; Nardelli B; Roschke V; Gottardi M; Zampieri F; Gherlinzoni F; Facchetti F; Pizzolo G; Cassatella MA
    Br J Haematol; 2007 Jun; 137(6):553-9. PubMed ID: 17539776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis.
    Visco C; Nadali G; Vassilakopoulos TP; Bonfante V; Viviani S; Gianni AM; Federico M; Luminari S; Peethambaram P; Witzig TE; Pangalis G; Cabanillas F; Medeiros LJ; Sarris AH; Pizzolo G
    Eur J Haematol; 2006 Nov; 77(5):387-94. PubMed ID: 16879607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy.
    Kim SJ; Lee SJ; Choi IY; Park Y; Choi CW; Kim IS; Yu W; Hwang HS; Kim BS
    Eur J Haematol; 2008 Sep; 81(3):177-84. PubMed ID: 18510703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Classical Hodgkin lymphoma, lymphocyte depleted type: clinicopathological analysis and prognostic comparison with other types of classical Hodgkin lymphoma.
    Karube K; Niino D; Kimura Y; Ohshima K
    Pathol Res Pract; 2013 Apr; 209(4):201-7. PubMed ID: 23478005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma.
    Diepstra A; van Imhoff GW; Karim-Kos HE; van den Berg A; te Meerman GJ; Niens M; Nolte IM; Bastiaannet E; Schaapveld M; Vellenga E; Poppema S
    J Clin Oncol; 2007 Jul; 25(21):3101-8. PubMed ID: 17536082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders.
    Novak AJ; Grote DM; Ziesmer SC; Kline MP; Manske MK; Slager S; Witzig TE; Shanafelt T; Call TG; Kay NE; Jelinek DF; Cerhan JR; Gross JA; Harder B; Dillon SR; Ansell SM
    J Clin Oncol; 2006 Feb; 24(6):983-7. PubMed ID: 16432079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcome.
    Herling M; Rassidakis GZ; Medeiros LJ; Vassilakopoulos TP; Kliche KO; Nadali G; Viviani S; Bonfante V; Giardini R; Chilosi M; Kittas C; Gianni AM; Bonadonna G; Pizzolo G; Pangalis GA; Cabanillas F; Sarris AH
    Clin Cancer Res; 2003 Jun; 9(6):2114-20. PubMed ID: 12796376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-Lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection.
    Fabris M; Quartuccio L; Sacco S; De Marchi G; Pozzato G; Mazzaro C; Ferraccioli G; Migone TS; De Vita S
    Rheumatology (Oxford); 2007 Jan; 46(1):37-43. PubMed ID: 16735452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma.
    Vassilakopoulos TP; Nadali G; Angelopoulou MK; Siakantaris MP; Dimopoulou MN; Kontopidou FN; Rassidakis GZ; Doussis-Anagnostopoulou IA; Hatzioannou M; Vaiopoulos G; Kittas C; Sarris AH; Pizzolo G; Pangalis GA
    Haematologica; 2001 Mar; 86(3):274-81. PubMed ID: 11255274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients.
    Diepstra A; van Imhoff GW; Schaapveld M; Karim-Kos H; van den Berg A; Vellenga E; Poppema S
    J Clin Oncol; 2009 Aug; 27(23):3815-21. PubMed ID: 19470931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic significance of beta(2)-microglobulin in patients with Hodgkin's lymphoma.
    Vassilakopoulos TP; Nadali G; Angelopoulou MK; Siakantaris MP; Dimopoulou MN; Kontopidou FN; Karkantaris C; Kokoris SI; Kyrtsonis MC; Tsaftaridis P; Pizzolo G; Pangalis GA
    Haematologica; 2002 Jul; 87(7):701-8; discussion 708. PubMed ID: 12091120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor.
    Weihrauch MR; Manzke O; Beyer M; Haverkamp H; Diehl V; Bohlen H; Wolf J; Schultze JL
    Cancer Res; 2005 Jul; 65(13):5516-9. PubMed ID: 15994922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus.
    Morel J; Roubille C; Planelles L; Rocha C; Fernandez L; Lukas C; Hahne M; Combe B
    Ann Rheum Dis; 2009 Jun; 68(6):997-1002. PubMed ID: 18676986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum level of intercellular adhesion molecule-1 in children with malignant lymphoma.
    Abdelrazik N; Fouda M; Zaghloul MH; Abbas D
    Med Princ Pract; 2008; 17(3):233-8. PubMed ID: 18408393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High pretreatment interleukin-10 is an independent predictor of poor failure-free survival in patients with Hodgkin's lymphoma.
    Salgami EV; Efstathiou SP; Vlachakis V; Sekara EV; Syrigos KN; Roussou PP
    Haematologia (Budap); 2002; 32(4):377-87. PubMed ID: 12803112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
    Petri M; Stohl W; Chatham W; McCune WJ; Chevrier M; Ryel J; Recta V; Zhong J; Freimuth W
    Arthritis Rheum; 2008 Aug; 58(8):2453-9. PubMed ID: 18668552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of CD20 expression in classical Hodgkin lymphoma: a clinicopathological study of 119 cases.
    Tzankov A; Krugmann J; Fend F; Fischhofer M; Greil R; Dirnhofer S
    Clin Cancer Res; 2003 Apr; 9(4):1381-6. PubMed ID: 12684408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
    Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
    Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphorylated STAT5 represents a new possible prognostic marker in Hodgkin lymphoma.
    Martini M; Hohaus S; Petrucci G; Cenci T; Pierconti F; Massini G; Teofili L; Leone G; Larocca LM
    Am J Clin Pathol; 2008 Mar; 129(3):472-7. PubMed ID: 18285272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression.
    Kelley TW; Pohlman B; Elson P; Hsi ED
    Am J Clin Pathol; 2007 Dec; 128(6):958-65. PubMed ID: 18024321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.